Table 2.

Clinical outcomes according to different BRCA1 status and different levels of stromal tumor-infiltrating lymphocytes

	No. of death	Overall survival (95% CI)	No. of distant recurrence or death	Distant recurrence-free survival (95% CI)	No. of second primary tumors	Cumulative incidence of second primary tumors (95% CI)
Tumor BRCA1-PM, sTILs < 50% (n = 77)
0 to 10 years	28	63.0 (53.0–74.9)	28	62.5 (52.4–74.5)	3	4.0 (0.0–8.3)
10 to 15 years	2	60.3 (50.2–72.4)	2	59.5 (49.3–71.9)	1	5.4 (0.1–10.3)
Tumor BRCA1-PM, sTILs ≥ 50% (n = 66)
0 to 10 years	2	97.0 (92.9–100.0)	1	98.5 (95.6–100.0)	3	4.5 (0.0–9.4)
10 to 15 years	0	97.0 (92.9–100.0)	0	98.5 (95.6–100.0)	2	7.6 (1.0–13.8)
gBRCA1m, sTILs < 50% (n = 61)
0 to 10 years	28	54.1 (42.9–68.2)	25	52.4 (40.3–68.0)	16	26.2 (15.0–36.0)
10 to 15 years	2	50.8 (39.7–65.0)	0	52.4 (40.3–68.0)	3	31.2 (19.5–41.2)
gBRCA1m, sTILs ≥ 50% (n = 44)
0 to 10 years	7	84.1 (73.9–95.6)	3	91.4 (82.5–100.0)	27	61.4 (44.8–73.0)
10 to 15 years	3	77.1 (65.6–90.7)	0	91.4 (82.5–100.0)	2	65.9 (49.6–77.0)
sBRCA1m, sTILs < 50% (n = 13)
0 to 10 years	6	53.8 (32.6–89.1)	7	46.2 (25.7–83.0)	0	0.0 (0.0–0.0)
10 to 15 years	0	53.8 (32.6–89.1)	0	46.2 (25.7–83.0)	0	0.0 (0.0–0.0)
sBRCA1m, sTILs ≥ 50% (n = 8)
0 to 10 years	1	87.5 (67.3–100.0)	1	87.5 (67.3–100.0)	1	12.5 (0.0–32.7)
10 to 15 years	0	87.5 (67.3–100.0)	0	87.5 (67.3–100.0)	0	12.5 (0.0–32.7)
BRCA1-non-altered, sTILs < 50% (n = 77)
0 to 10 years	25	66.2 (56.3–77.9)	25	66.0 (56.1–77.8)	5	6.8 (0.9–12.3)
10 to 15 years	4	60.8 (50.6–73.0)	3	61.4 (51.1–73.8)	4	12.3 (4.6–19.4)
BRCA1-non-altered, sTILs ≥ 50% (n = 66)
0 to 10 years	7	85.7 (76.4–96.1)	4	91.0 (82.9–99.8)	6	12.2 (2.6–20.9)
10 to 15 years	1	83.6 (73.8–94.7)	0	91.0 (82.9–99.8)	2	16.3 (5.4–26.0)

Abbreviations: tumor BRCA1-PM, tumor BRCA1 promoter methylation; sTILs, stromal tumor-infiltrating lymphocytes; gBRCA1m, germline BRCA1 mutation; BRCA1-non-alteration, tumor without germline BRCA1 mutation, somatic BRCA1 mutation, or tumor BRCA1 promoter methylation; CI, confidence interval